Buloxibutid Explained

Legal Status:	Investigational
Cas Number:	477775-14-7
Pubchem:	9804984
Drugbank:	DB18038
Chemspiderid:	7980744
Unii:	RC2V4W0EYC
Chembl:	189568
Synonyms:	VP-01
Iupac Name:	butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
C:	23
H:	29
N:	3
O:	4
S:	2
Smiles:	CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3
Stdinchi:	1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27)
Stdinchikey:	XTEOJPUYZWEXFI-UHFFFAOYSA-N

Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.^[1] It is an angiotensin II receptor type 2 agonist.^[2]

Notes and References

Web site: Buloxibutid - Vicore Pharma . AdisInsight . Springer Nature Switzerland AG .
Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, Dalsgaard CJ . Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist . Clinical and Translational Science . 17 . 2 . e13735 . February 2024 . 38344891 . 10859786 . 10.1111/cts.13735 .